HY-124045 Search Results


diminazene  (MedChemExpress)
94
MedChemExpress diminazene
Diminazene, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/diminazene/product/MedChemExpress
Average 94 stars, based on 1 article reviews
diminazene - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
sphk1 agonist k6pc 5  (MedChemExpress)
93
MedChemExpress sphk1 agonist k6pc 5
Ritanserin suppresses the phospholipase D (PLD) signaling pathway in AML cells. A The PLD signaling pathway is enriched in the high-risk group, of which DGKα and <t>SphK1</t> are jointly involved in signal transduction of the PLD signaling pathway. B The protein expression levels of DGKα, SphK1 and p-SphK1(Ser225) after ritanserin treatment for 48 h. The histograms of cell viability and apoptosis cell ratio after ritanserin combined with exogenous C phosphatidic acid or D SphK1 agonist <t>(K6PC)</t> for 48 h. Data are presented as the mean ± S.D. of triplicate experiments. (*p < 0.05; **p < 0.01; ***p < 0.001.) E Western blotting indicated the expression of SphK1 and p-SphK1(Ser225) after ritanserin combined with exogenous phosphatidic acid or K6PC for 48 h
Sphk1 Agonist K6pc 5, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sphk1 agonist k6pc 5/product/MedChemExpress
Average 93 stars, based on 1 article reviews
sphk1 agonist k6pc 5 - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier

Image Search Results


Ritanserin suppresses the phospholipase D (PLD) signaling pathway in AML cells. A The PLD signaling pathway is enriched in the high-risk group, of which DGKα and SphK1 are jointly involved in signal transduction of the PLD signaling pathway. B The protein expression levels of DGKα, SphK1 and p-SphK1(Ser225) after ritanserin treatment for 48 h. The histograms of cell viability and apoptosis cell ratio after ritanserin combined with exogenous C phosphatidic acid or D SphK1 agonist (K6PC) for 48 h. Data are presented as the mean ± S.D. of triplicate experiments. (*p < 0.05; **p < 0.01; ***p < 0.001.) E Western blotting indicated the expression of SphK1 and p-SphK1(Ser225) after ritanserin combined with exogenous phosphatidic acid or K6PC for 48 h

Journal: Discover. Oncology

Article Title: Ritanserin suppresses acute myeloid leukemia by inhibiting DGKα to downregulate phospholipase D and the Jak-Stat/MAPK pathway

doi: 10.1007/s12672-023-00737-9

Figure Lengend Snippet: Ritanserin suppresses the phospholipase D (PLD) signaling pathway in AML cells. A The PLD signaling pathway is enriched in the high-risk group, of which DGKα and SphK1 are jointly involved in signal transduction of the PLD signaling pathway. B The protein expression levels of DGKα, SphK1 and p-SphK1(Ser225) after ritanserin treatment for 48 h. The histograms of cell viability and apoptosis cell ratio after ritanserin combined with exogenous C phosphatidic acid or D SphK1 agonist (K6PC) for 48 h. Data are presented as the mean ± S.D. of triplicate experiments. (*p < 0.05; **p < 0.01; ***p < 0.001.) E Western blotting indicated the expression of SphK1 and p-SphK1(Ser225) after ritanserin combined with exogenous phosphatidic acid or K6PC for 48 h

Article Snippet: The protein agonists applied were as follows: SphK1 agonist K6PC-5(HY-124042, MedChemExpress); MEK/ERK agonists C16-PAF (HY-108635, MedChemExpress); JAK/STAT agonists RO8191 (T22142, TargetMol).

Techniques: Transduction, Expressing, Western Blot